Bifendate treatment attenuates hepatic steatosis in cholesterol/bile salt- and high-fat diet-induced hypercholesterolemia in mice

Pan, Si-Yuan; Yang, Rong; Dong, Hang; Yu, Zhi‐Ling; Ko, Kam-Ming

doi:10.1016/j.ejphar.2006.09.011

Cited by 51 publications

(38 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results show that phillygenin/OFE exerts a beneficial effect on antioxidant enzymes ( p < 0.01). The activities of AST, SOD, and MDA after treatment with the lowest dosage of phillygenin/OFE showed almost the same levels after treatment with bifendate, the potent hepatoprotective drug used as positive control [16–18]. …”

Section: Resultsmentioning

confidence: 99%

Evaluation of the Pharmacokinetics and Hepatoprotective Effects of Phillygenin in Mouse

Song

et al. 2018

BioMed Research International

View full text Add to dashboard Cite

Phillygenin is a bioactive intergradient in Osmanthus fragrans, a well-known food additive and Chinese traditional medicine. This study was to investigate the hepatoprotective effects and pharmacokinetics of phillygenin. The hepatoprotective effect of phillygenin was assessed in carbon tetrachloride- (CCl4-) intoxicated mice by monitoring levels of serum and tissue biomarkers. The pharmacokinetics of phillygenin was evaluated in the mouse after oral (po, 24 mg / kg) or intravenous (iv, 12 mg/kg) administration. Results showed that phillygenin has a great hepatoprotective effect on CCl4-induced liver injury in mice owing to its antioxidant activity and inhibition on cytochrome P450 2E1(CYP2E1). After oral administration, phillygenin was efficiently absorbed with the oral bioavailability of 56.4%. Two metabolites, hydroxylated and dimethylated phillygenin, were identified in mouse urine. These results suggested that phillygenin could be explored as new and potential natural antioxidants and hepatoprotective agents.

show abstract

Section: Resultsmentioning

confidence: 99%

Evaluation of the Pharmacokinetics and Hepatoprotective Effects of Phillygenin in Mouse

Song

et al. 2018

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…However, changes in blood triglyceride levels in animals fed with a high-fat diet were not consistent; increased (Lin et al 2009a), unchanged (Gopal et al 2010;Lin et al 2009b), and reduced blood triglyceride levels (Pan et al 2006c;Lee et Fig. 4 Histological examination of liver tissues in mice treated with schisandrin B and/or fenofibrate (H & E, original magnification ×20).…”

Section: Discussionmentioning

confidence: 95%

Effective kinetics of schisandrin B on serum/hepatic triglyceride and total cholesterol levels in mice with and without the influence of fenofibrate

Pan

Dong

Guo

et al. 2011

Naunyn-Schmiedeberg's Arch Pharmacol

Self Cite

View full text Add to dashboard Cite

Schisandrin B, an active ingredient isolated from the fruit of Schisandra chinensis, increased serum and hepatic triglyceride levels in mice. In the present study, the effective kinetics of schisandrin B on serum/hepatic triglyceride and total cholesterol levels in mice without and with the influence of fenofibrate were investigated. Parameters on hepatic index (the ratio of liver weight to body weight × 100) were also analyzed. Mice were intragastrically treated with schisandrin B at a single dose of 0.2, 0.4, 0.8, or 1.6 g/kg, without or with fenofibrate pretreatment (0.1 g/kg/day for 4 days, p.o.). Twenty-four hours after schisandrin B treatment, serum/hepatic triglyceride and total cholesterol levels were measured. Schisandrin B treatment dose-dependently increased serum and hepatic triglyceride levels as well as hepatic index in mice. In contrast, hepatic total cholesterol levels were decreased in a dose-dependent manner in schisandrin B-treated mice. Data obtained from effective kinetics analysis indicated that the action of schisandrin B on serum triglyceride had a higher specificity than those on hepatic total cholesterol and hepatic index. While fenofibrate pretreatment inhibited the schisandrin B-induced elevation in serum triglyceride levels, it completely abrogated the elevation of hepatic triglyceride levels in schisandrin B-treated mice. The combined treatment with schisandrin B and fenofibrate decreased hepatic total cholesterol level and increased the hepatic index in an additive or semi-additive manner, respectively. In conclusion, the results of effective kinetics analysis indicated that the schisandrin B-induced hypertriglyceridemia was competitively inhibited by fenofibrate. Schisandrin B may offer the prospect of setting up a mouse model of hypertriglyceridemia and fatty liver for screening triglyceride-lowering drug candidates.

show abstract

“…Bifendate (biphenyldicarboxylate), a known hepatoprotective agent, was used as the reference standard (Pan et al, 2006). The 60 mice were grouped randomly as follows: At the end of the treatment, body weight and relative liver weight were measured; blood samples of each animal were collected in sterile centrifuge tubes and allowed to clot.…”

Section: Hepatoprotective Activitymentioning

confidence: 99%

Protective activity of Jiang-Zhi-Li-Gan against carbon tetrachloride-induced hepatic injury in mice

Zhai

Bian

2010

Pharmaceutical Biology

View full text Add to dashboard Cite

The administration of carbon tetrachloride (CCl(4)) to mice produced hepatotoxicity, showing a significant increase in the serum levels of alanine transaminase (ALT) and aspartate aminotransferase (AST). Mice pretreated with Jiang-Zhi-Li-Gan (JZLG, 100-900 mg/kg, p.o.), a domestic remedy for liver disease in Rui-Jin Hospital, showed a significant decrease in serum ALT and AST levels when compared to the group treated with CCl(4) alone. The standard drug, bifendate (200 mg/kg, p.o.), also exhibited similar results. In the acute toxicity study, JZLG did not show any mortality up to a dose of 32 g/kg body weight. Based on the results obtained, it can be concluded that JZLG seems to possess hepatoprotective activity in mice. These results support the use of this prescription against chemical hepatic injury.

show abstract

Bifendate treatment attenuates hepatic steatosis in cholesterol/bile salt- and high-fat diet-induced hypercholesterolemia in mice

Cited by 51 publications

References 28 publications

Evaluation of the Pharmacokinetics and Hepatoprotective Effects of Phillygenin in Mouse

Evaluation of the Pharmacokinetics and Hepatoprotective Effects of Phillygenin in Mouse

Effective kinetics of schisandrin B on serum/hepatic triglyceride and total cholesterol levels in mice with and without the influence of fenofibrate

Protective activity of Jiang-Zhi-Li-Gan against carbon tetrachloride-induced hepatic injury in mice

Contact Info

Product

Resources

About